

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Lin Zhi *et al.*  
Serial No. : 10/684,212  
Conf. No. : 8674  
Filed : October 10, 2003

Art Unit : 1625  
Examiner : Charanjit Aulakh  
Cust. No. : 20985

Title : **5-SUBSTITUTED 7,9-DIFLUORO-5H-CHROMENO [3,4-F]  
QUINOLINE COMPOUNDS AS SELECTIVE PROGESTERONE  
RECEPTOR MODULATOR COMPOUNDS**

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN  
ACCORDANCE WITH 37 C.F.R. §§ 1.97-1.98**


This Information Disclosure Statement is filed concurrent with a Request for Continued Examination. Thus, a fee for filing this statement should not be due. If, however, it is determined that a fee is due, the Office is hereby authorized to charge any fees that may be due in connection with filing this paper to Deposit No. 06-1050.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all information known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Forms PTO-1449 (2 pages) and copies of the cited non U.S. Patent documents are provided herewith.

All the documents cited on the Form PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**  
"Express Mail" Mailing Label Number EV 399317280 US  
Date of Deposit: **August 17, 2005**

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Mail Stop RCEt, Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

  
Stephanie Seidman

Applicant : Zhi *et al.*  
Serial No. : 10/684,212  
Filed : October 10, 2003



Attorney's Docket No.: 18202-048001 / 1087  
Information Disclosure Statement

Applicant also makes known to the Examiner the following pending U.S. and International Applications that have one or more common inventors and/or are commonly owned:

<b><u>Docket No.</u></b>	<b><u>U.S.S.N.</u></b>	<b><u>Filed</u></b>	<b><u>Publ. No.</u></b>
002007/1002F	08/141,246	10/22/93	n/a
002009/1002H	08/141,496	10/22/93	n/a
003014/1014N	10/739,933	12/17/03	n/a
004002/1026B	08/484,487	06/07/95	n/a
004003/1026C	10/847,732	05/17/04	2004-0209839
005003/1028C	10/360,580	02/05/03	20040019072
007002/1033B	09/277,405	03/26/99	n/a
009001/1042	08/883,115	06/26/97	n/a
013002/1062B	10/238,363	09/09/02	20030186970
014002/1066B	10/329,307	12/23/02	20030149268
015002/1073B	10/299,909	11/18/02	20030130505
017001/1081	10/080,926	02/22/02	20020183346
018001/1082	10/080,503	02/22/02	20020183314
020001/1088	10/684,229	10/10/03	20040152718
033001/1051	09/463,542	01/21/00	n/a
035002/1059B	10/229,649	08/27/02	20030013766
046003/1057C	09/866,025	05/25/01	n/a
048001/1087	10/684,212	10/10/03	20040152717
051001/1814	10/211,969	08/01/02	n/a
057001/1091	10/684,227	10/10/03	20040147530

<b><u>Docket No.</u></b>	<b><u>Intl. No.</u></b>	<b><u>Filed</u></b>	<b><u>Publ. No.</u></b>
022WO1/1096PC	PCT/US04/022907	07/16/04	2005/017185
023WO1/1097PC	PCT/US04/023788	07/16/04	2005/009104
024WO1/1098PC	PCT/US04/023093	07/16/04	2005/016255
026WO1/1100PC	PCT/US04/023010	07/16/04	2005/010202
027WO1/1110PC	PCT/US2005/06627	02/24/05	Awaiting
028WO1/1112PC	PCT/US2005/07867	3/11/05	Awaiting
030WO1/1111PC	PCT/US04/027483	08/23/04	2005/018573

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall


Applicant : Zhi *et al.*  
Serial No. : 10/684,212  
Filed : October 10, 2003

Attorney's Docket No.: 18202-048001 / 1087  
**Information Disclosure Statement**

not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing references and they be made of record in the file history of the above-captioned application.

Respectfully submitted,



---

Stephanie Seidman  
Reg. No. 33,779

Attorney Docket No. 18202-048001 / 1087

**Address all correspondence to:**

Stephanie Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-5070  
Facsimile: (202) 626-7796  
email: seidman@fr.com

Sheet 1 of 2

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18202-048001/1087	Application No. 10/684,212
		Applicant Lin Zhi <i>et al.</i>	
		Filing Date October 10, 2003	Group Art Unit 1625

**List of Patents and Publications for Applicant's  
Information Disclosure Statement**

(37 CFR §1.98(b))

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	20040147530	10/10/03	Zhi et al.	514	256	10/10/03
	AB	20040152718	08/05/04	Zhi et al.	514	285	10/10/03
	AC	5,506,102	04/09/96	McDonnell et al.	435	6	10/28/93
	AD	5,994,544	11/30/99	Jones et al.	546	62	10/08/97
	AE	6,093,826	07/25/00	Edwards et al.	546	62	06/08/98
	AF	6,268,497	07/31/01	Edwards et al.	546	62	04/12/00
	AG	6,380,207	04/30/02	Coghlan et al.	514	285	02/13/98
	AH	6,448,405	09/10/02	Jones et al.	546	62	10/08/97
	AI	6,506,766	01/14/03	Coghlan et al.	514	285	07/05/00
	AJ	6,696,459	02/24/04	Jones et al.	514	285	10/14/97

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AK	200202565	06/27/01	PCT				
	AL	2004033459	04/22/04	PCT				
	AM	2004033460	04/22/04	PCT				
	AN	2004033461	04/22/04	PCT				
	AO	9619458	06/27/96	PCT				

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AP	Clemm et al., "Definition of the critical cellular components which distinguish between hormone and antihormone activated progesterone receptor," <i>Journal of Steroid Biochemistry and Molecular Biology</i> 53(1-6):487-495. (1995)
	AQ	Edwards et al., "5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: the effect of D-ring substituents," <i>Journal of Medicinal Chemistry</i> . 41(3):303-310 (1998)
	AR	Edwards et al., "Preparation, resolution, and biological evaluation of 5-aryl-1, 2-dihydro-5H-chromeno[3,4-f]quinolines: potent, orally active, nonsteroidal progesterone receptor agonists," <i>Journal of Medicinal Chemistry</i> 41(15):2779-2785 (1998)

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Mailed August 17, 2005

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18202-048001/1087	Application No. 10/684,212
List of Patents and Publications for Applicant's Information Disclosure Statement		Applicant Lin Zhi <i>et al.</i>	
		Filing Date October 10, 2003	Group Art Unit 1625

(37 CFR §1.98(b))

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AS	Hamann et al., "Nonsteroidal progesterone receptor antagonists based on a conformationally-restricted subseries of 6-aryl-1,2-dihydro-2,2,4-trimethylquinolines," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 8(19):2731-2736 (1998)
	AT	McDonnell et al., "Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors," <i>Seminars in Cancer Biology</i> , 5(5):327-336 (1994)
	AU	Miner, J. N. and C.M. Tyree, "Drug discovery and the intracellular receptor family," <i>Vitamins and Hormones</i> . 62:253-280. (2001)
	AV	Rosen et al., "Intracellular receptors and signal transducers and activators of transcription superfamilies - novel targets for small-molecule drug discovery," <i>Journal of Medicinal Chemistry</i> 38(25):4855-4874 (1995)
	AW	Santiso-Mere, D. and D.P. McDonnell, "Applied nuclear receptor research in the drug discovery process," <i>Chimica Oggi</i> . 12(5-6):29-36. (1994)
	AX	Silverman, R.B., "Prodrugs and Drug Delivery Systems," Chapter 8 in <i>The Organic Chemistry of Drug Design and Drug Action</i> , San Diego: Academic Press, Inc., pp. 352-401 (1992)
	AY	Tegley et al., "5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists," <i>Journal of Medicinal Chemistry</i> . 41(22):4354-4359. (1998)
	AZ	Vegeto et al., "Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function," <i>Molecular Endocrinology</i> . 7(10):1244-1255. (1993)
	BA	Wagner et al., "The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: Implications for the development of dissociated antiprogestins," <i>Endocrinology</i> 140(3):1449-1458 (1999)
	BB	Wen et al., "The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells," <i>Molecular and Cellular Biology</i> 14(12):8356-8364 (1994)
	BC	Zhi, L. and K.B. Marschke, "Novel class of non-steroidal progesterone receptor antagonists," <i>Expert Opinion on Therapeutic Patents</i> . 9(6):695-700 (1999)
	BD	Zhi et al., "5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 8(23):3365-3370 (1998)
	BE	Zhi, et al. "Synthesis and Biological Activity of 5-Methylidene 1,2-Dihydrochromeno[3,4-f]quinoline Derivatives as Progesterone Receptor Modulators" <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 13:2071-2074 (2003).
	BF	Zhi et al., "5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists," <i>Journal of Medicinal Chemistry</i> 41(3):291-302 (1998)
	BG	Zhi et al., "5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists: effect of A-ring modification," <i>Journal of Medicinal Chemistry</i> . 42(8):1466-1472 (1999)
	BH	Zhi et al., "5-Benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as Selective Progesterone Receptor Modulators," <i>Journal of Medicinal Chemistry</i> 46(19):4104-4112 (2003)

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Mailed August 17, 2005